Individualizing antihypertensive combination therapies: Clinical and hemodynamic considerations

Current Hypertension Reports

Volumn 16, Issue 7, 2014, Pages

  Taler, Sandra J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bioimpedance; Hemodynamics; Hypertension treatment; Protocol based therapy; Resistant hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; FLUID RETENTION; HEART OUTPUT; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; IMPEDANCE CARDIOGRAPHY; MEDICATION COMPLIANCE; PATIENT CODING; PERSONALIZED MEDICINE; PLASMA RENIN ACTIVITY; POLYPHARMACY; REIMBURSEMENT; RENIN RELEASE; RESISTANT HYPERTENSION; SODIUM RETENTION; SYSTEMIC VASCULAR RESISTANCE; VASOCONSTRICTION; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; HEMODYNAMICS; PHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HEMODYNAMICS; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE;

EID: 84901730684     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0451-y     Document Type: Article

References (29)

1. James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J, et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-20.
2. National Institute for Health and Clinical Excellence (NICE): Hypertension: The clinical management of primary hypertension in adults. 2011.
3. •• Frieden T. Protocol-Based Treatment of Hypertension: A Critical Step on the Pathway to Progress. JAMA. 2014;311:21-2. Viewpoint arguing for standardized treatment approaches to hypertension using protocols, algorithms and care pathways.
4. Taler SJ, Textor SC, Augustine JE. Resistant Hypertension: Comparing hemodynamic management to specialist care. Hypertension. 2002;39:982-8. (Pubitemid 34547797)
5. Smith R, Levy P. Ferrario, C, for the Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group: Value of Noninvasive Hemodynamics to Achieve Blood Pressure Control in Hypertensive Subjects. Hypertension. 2006;47:771-7.
6. •• Krzesiński P, Gielerak G, Kowal J. A "patient-tailored" treatment of hypertension with use of impedance cardiography: A randomized, prospective and controlled trial. Med Sci Monit. 2013;19:242-50. The most recent randomized trial using hemodynamic measurements to guide hypertension treatment in patients with mild to moderate hypertension.
7. Tarazi RC. The hemodynamics of hypertension. In: Genest J, Kuchel O, Hamet P, Cantin M, editors. Hypertension: physiopathology and treatment. 2nd ed. New York: McGraw-Hill Book Company; 1983. p. pp 15-42.
8. Lund-Johansen, P: Hemodynamic effects of antihypertensive agents. In: Handbook of Hypertension. edited by DOYLE, A. E., Elsevier Science Publishers B.V., 1988, pp 41-72.
9. Struyker Boudier H. The interaction of antihypertensive drugs with mechanisms of blood pressure regulation. In: Von Zwieten P, editor. Pharmacology of antihypertensive drugs. Amsterdam: Elsevier; 1984. p. pp 46-65.
10. Laragh JH. Lesson XVI: How to choose the correct drug treatment for each hypertensive patient using a plasma renin-based method and the volume-vasoconstriction analysis. AmJHyper. 2001;14:491-503.
11. Laragh J, Sealey J. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24:1164-80.
12. Egan B, Basile J, Rehman S, Davis P, Grob III C, Riehle J, et al. Plasma Renin Test-Guided Drug Treatment Algorithm for Correcting Patients With Treated but Uncontrolled Hypertension: A Randomized Controlled Trial. Am J Hypertens. 2009;22:792-801.
13. Brown MJ, Cruickshank JK, Dominczak AF, MacGregor G, Poulter NR, Russell GI, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens. 2003;17:81-6. (Pubitemid 36292361)
14. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS-Y, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 2002;20:771-7. (Pubitemid 34913723)
15. Grim CE. Evolution of diagnostic criteria for primary aldosteronism: Why is it more common in "drug-resistant" hypertension today? Curr Hypertens Rep. 2004;6:485-92. (Pubitemid 39600105)
16. Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med. 2005;5:55-60. (Pubitemid 40313733)
17. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Lowrenin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217-26. (Pubitemid 39463817)
18. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hyper. 2003;16:925-30. (Pubitemid 37315491)
19. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. AmJHyper. 2002;15:333-9. (Pubitemid 34408973)
20. Dustan HP, Tarazi RC, Bravo EL. Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Eng J Med. 1972;286:861-6.
21. Finnerty Jr FA, Davidov M, Mroczek WJ, Gavrilovich L. Influence of extracellular fluid volume on response to antihypertensive drugs. Circ Res. 1970;XXVI-XXVII:I-71-82.
22. Dustan HP. Causes of inadequate response to antihypertensive drugs: Volume factors. Hypertension. 1983;5:III-26-30.
23. Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. Br MedJ. 1980;281:1101-3. (Pubitemid 10021412)
24. Graves JW, Bloomfield RL, Buckalew VM. Plasma volume in resistant hypertension: Guide to pathophysiology and therapy. Am J Med Sci. 1989;298:361-5. (Pubitemid 20026468)
25. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. JCardiovascPharmacol. 1987;10:S121-31. (Pubitemid 17106206)
26. Ventura H, Taler SJ, Strobeck J. Hypertension as a hemodynamic disease: The role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. Am J Hypertens. 2005;18:26S-43.
27. Johns DW, Peach MJ. Factors that contribute to resistant forms of hypertension: Pharmacological considerations. Hypertension. 1988;11:II-88-95.
28. Ferrario C, Flack J, Strobeck J, Smits G, Peters C. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. Ther Adv Cardiovasc Dis. 2010;4:5-16.
29. Frieden T, Berwick D. The "Million Hearts" Initiative - Preventing Heart Attacks and Strokes. NEJM. 2011;365(e27):21-4.